Ixazomib-based induction regimens plus ixazomib maintenance in transplant-ineligible, newly diagnosed multiple myeloma: the phase II, multi-arm, randomized UNITO-EMN10 trial
Mina R.
•
Falcone A. P.
•
Bringhen S.
altro
Larocca A.
2021